TrialSignal
Clinical trial intelligence report
Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF 5074 in Healthy Young Male Subjects
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00954252
Status
COMPLETED
Phase
Phase 1
Sponsor
CERESPIR
Executive brief
Investment-Ready Snapshot
CHF 5074, developed by CERESPIR, is positioned as a novel gamma-secretase modulator aimed at treating Alzheimer's disease by reducing amyloid-beta levels. The Alzheimer's disease market is projected to grow significantly, driven by increasing prevalence and demand for effective therapies. The competitive landscape includes several established players and emerging biotech firms focused on similar mechanisms. Given the high unmet need in Alzheimer's treatment, successful outcomes in this trial could enhance CERESPIR's market position and attract potential partnerships or acquisition interest. Diligence should focus on the safety profile and pharmacokinetic data to assess viability for further development.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00954252
Indication
Alzheimer's Disease
Modality
small molecule
Target
Gamma-secretase modulator, specifically targeting amyloid precursor protein (APP) processing to reduce amyloid-beta (Aβ) production.
Intervention
CHF 5074, placebo, CHF 5074, CHF 5074, CHF 5074, CHF 5074, CHF 5074
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.